Ipsen, GSK and Alexion Pharmaceuticals provide key case studies on optimizing and validating your lyophilisation cycle | 7-8 July 2014, London, UK

Join SMi Group's 2nd annual Lyophilisation forum taking place on 7-8 July, London, and gain insight into current successes and challenges that leading pharmaceutical and biotechnology organisations are facing during their freeze drying life cycles, including GlaxoSmithKline, Novo Nordisk, Boehringer Ingelheim, MedImmune, Ipsen, Norgine, GEA Pharma Systems and more.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friendRepost This

2nd Annual Lyophilisation 2014

Today, exact dosing and substance utilisation is possible even with small filling volumes.

London, Southwark (PRWEB UK) 3 May 2014

Freeze-drying is a complex process that has evolved considerably over the past years and has proven its worth in the market. Today, exact dosing and substance utilisation is possible even with small filling volumes. Nevertheless, freeze-drying a product is quite complexand takes place in several steps. A solution is first prepared which hascertain thermal properties that will in turn suggest lyophilisation temperatures and pressure.

(Source: International Pharmaceutical Industry (IPI), Developing a Lyophilised Portfolio, 2014)

Key Case Studies Include:

Fill finish Lyophilisation
Mr Bertie Daly, Associate Director, Sterile Fill finish, Alexion Pharmaceuticals

  • Increasing stability / shelf life
  • Lyophilisation cycle time and running sequence
  • Proposals for lyophilisation optimisation: costs versus benefits of optmising the lyophilisation process

3-stage validation approach for Lyophilized products
Massimo Rastelli, Project Leader Biopharm, GSK

  • Evaluating technology transfer of an existing commercial product
  • Developing a new lyophilised product
  • Discussion of advances in the lyophilisation field

How to handle all freeze drying manufacturing equipment
Julie Pagenaud, Sterile Product Manufacturing Manager, Ipsen

  • Challenge of investment: new machine vs retrofitting / revamping
  • Qualification & validation strategies based on risk analysis appraoch
  • Project case study: from user requirements to manufacturing

SMi's 2nd annual Lyophilisation conference on 7-8 July 2014, London, will provide an update on advances within lyophilisation. We will examine the latest techniques and industry case studies to manage your lyophilisation cycle effectively. With a workshop and sessions led by experts, you will gain an array of tools and tips to deliver the best outcome for your organisation.

Some of the confirmed attendees so far include: Boehringer Ingelheim, Allembis, Explicat Pharma, MedImmune, Novo Nordisk, GlaxoSmithKline, Norgine, Alexion Pharmaceuticals, Ellab, Ipsen, Ghent University, GEA Pharma Systems, GEA Process Engineering, Bavarian Nordic, Imperial College London, Newcastle University, plus many more.

For those that are interested there is currently a £100 early bird discount available online.

Lyophilisation 2014: Pharmaceuticals & Biopharmaceuticals
7-8 July, 2014
Marriott Regents Park Hotel, London, UK
http://www.lyophilisation-conference.com

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries.

We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. We hold events in over 30 major cities throughout the world including London, Paris and Singapore and to date have welcomed over 200,000 participants from 80 countries.

More information can be found at http://www.smi-online.co.uk.


Contact